Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial
Résumé
BACKGROUND: Mass azithromycin administration has been used to reduce under-five mortality in sub-Saharan Africa, but concerns remain about its potential impact on antimicrobial resistance (AMR). METHODS AND FINDINGS: The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regiments with Azithromycin (LAKANA) trial was a cluster-randomized, placebo-controlled trial conducted in Mali, enrolling infants aged 1-11 months randomized to placebo, twice-yearly azithromycin, or quarterly azithromycin for 2 years. The trial did not find any mortality benefit amongst treated children. The current analysis is a sub-study of the parent trial examining AMR outcomes. Repeated cross-sectional nasopharyngeal and rectal swabs were collected from children aged 4-14-months in villages randomized to placebo, twice-yearly or quarterly azithromycin, and from untreated contacts aged 49-59-months at baseline, 12-, 24-, and 36-months post-village enrollment across 59 LAKANA trial villages. Phenotypic resistance to macrolide and nonmacrolide antibiotics was assessed in Streptococcus pneumoniae (S. pneumoniae) and Escherichia coli (E. coli) isolates using disk diffusion or E-tests. The primary noninferiority analysis evaluated macrolide resistance prevalence at 36-months among younger children and at 24-months among older contacts, with predefined margin of +10 percentage points. A total of 5,025 nasopharyngeal and 5,021 rectal samples were analyzed. At baseline, among 4-14-month-old children, macrolide resistance in S. pneumoniae was 16.6%, 15.5%, and 11.1% in the placebo, twice-yearly and quarterly azithromycin groups, respectively, and 5.0%, 5.0%, and 0.0% in E. coli. At 36-months, corresponding prevalences were 13.4%, 14.5%, and 17.2% for S. pneumoniae, and 5.1%, 6.4%, and 9.1% for E. coli. The difference between placebo and twice-yearly groups was 1.0% (95% CI [-4.7, 6.8]) for S. pneumoniae and 1.3% (95% CI [-2.4, 4.9]) for E. coli; corresponding differences for quarterly azithromycin group was 3.8% (95% CI [-3.3, 10.9]) for S. pneumoniae and 4.0% (95% CI [-0.7, 8.7]) for E. coli. Among untreated older children, there were no marked inter-group differences in macrolide resistance either at baseline or at 24-months. The study may not have been large enough to detect a small increase in macrolide resistance in S. pneumoniae among young children in villages that received quarterly azithromycin. CONCLUSIONS: Twice-yearly azithromycin administration to 1-11-month-old infants for 2 years in Mali did not increase macrolide resistance in treated children or untreated contacts and met the predefined noninferiority margin in tested isolates. Quarterly administration, however, cannot exclude a modest dose-dependent increase of macrolide resistance in S. pneumoniae and E. coli.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 16/11/2026. Le document reste hébergé par sa source.
Voir le document à la source →